HC Wainwright Predicts Weaker Earnings for Apyx Medical

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Apyx Medical to a loss of $0.07 per share from $0.06, while maintaining a Buy rating and $7.00 price target.
• Apyx Medical’s latest results beat expectations, reporting a $0.07-per-share loss versus the projected $0.08 loss and revenue of $13.88 million versus the $13.18 million consensus estimate.
• The stock was trading down 14.6% at $3.46, despite a MarketBeat consensus rating of Moderate Buy and an average analyst price target of $6.60; the company remains unprofitable with a negative 14.78% net margin.

Apyx Medical Corporation (NASDAQ:APYX - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Apyx Medical in a research note issued to investors on Friday, August 7th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). HC Wainwright currently has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Apyx Medical's current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Apyx Medical's Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.25) EPS.

Apyx Medical (NASDAQ:APYX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%.

Several other analysts have also recently weighed in on APYX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Apyx Medical from a "buy" rating to a "hold" rating in a research note on Sunday, April 26th. Finally, Zacks Research raised Apyx Medical to a "hold" rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $6.60.

Apyx Medical Trading Down 14.6%

Shares of APYX stock opened at $3.46 on Tuesday. Apyx Medical has a 12-month low of $1.70 and a 12-month high of $5.08. The company has a market capitalization of $145.74 million, a P/E ratio of -17.30 and a beta of 1.39. The firm has a 50-day moving average price of $4.23 and a 200 day moving average price of $3.94. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19.

Hedge Funds Weigh In On Apyx Medical

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in shares of Apyx Medical during the third quarter valued at approximately $28,000. Nwam LLC bought a new position in Apyx Medical in the 1st quarter worth approximately $47,000. Osaic Holdings Inc. acquired a new position in Apyx Medical during the 2nd quarter worth $50,000. Franklin Resources Inc. bought a new position in Apyx Medical in the 3rd quarter valued at $59,000. Finally, Hudson Bay Capital Management LP bought a new position in Apyx Medical in the 4th quarter valued at $73,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source